Preparing your space
Preparing your space
Conditions & Recovery · Oncology Brothers · June 1, 2026
Join us as we bring you the latest insights from ASCO 2026! In this episode, we dived deep into the groundbreaking RASolute-302 study, which has made waves in the treatment of metastatic pancreatic cancer. Discover how the novel RAS inhibitor, Daraxonrasib, has doubled overall survival rates from 6.7 months to an impressive 13.2 months for patients in the second-line setting. Listen us on:Spotify:
Originally published by Oncology Brothers. We curate and add context; they did the reporting.
Read the full story at Oncology Brothers ↗